Home - Products - Others - Other Targets - Dihydrokaempferol 3-O-glucoside

Dihydrokaempferol 3-O-glucoside

CAS No. 31049-08-8

Dihydrokaempferol 3-O-glucoside( ——— )

Catalog No. M39499 CAS No. 31049-08-8

Dihydrokaempferol-3-O-β-D-glucoside (Compound 3) is a compound that can be isolated from the bark of Cudrania tricuspidata (Carr.) Bur..

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 426 In Stock
25MG Get Quote In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Dihydrokaempferol 3-O-glucoside
  • Note
    Research use only, not for human use.
  • Brief Description
    Dihydrokaempferol-3-O-β-D-glucoside (Compound 3) is a compound that can be isolated from the bark of Cudrania tricuspidata (Carr.) Bur..
  • Description
    Dihydrokaempferol-3-O-β-D-glucoside (Compound 3) is a compound that can be isolated from the bark of Cudrania tricuspidata (Carr.) Bur..
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    31049-08-8
  • Formula Weight
    450.39
  • Molecular Formula
    C21H22O11
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zheng Z P, et al. Water‐Soluble Constituents of Cudrania tricuspidata (Carr.) BurJ. Journal of Integrative Plant Biology, 2006, 48(8): 996-1000.
molnova catalog
related products
  • dihydrocarveol

    dihydrocarveol is?Fragrance material.

  • Filixic acid ABA

    Filixic acid ABA exhibits inhibitory effects on neuraminidase of influenza virus H5N1 with IC50 as 29.57 ± 2.48 μM, it may have anti-influenza virus activity.

  • GDC-0623

    GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.